---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-032271"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2026-10-07T13:06:30+00:00"
generated_at: "2026-10-12T15:57:33.307982+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences hits 164-patient enrollment target in NANOPULSE-AF pivotal AF trial, 3 months early

## Summary
- NANOPULSE-AF IDE pivotal study enrolled 164 evaluable patients across 15 clinical sites, evaluating the nPulse Cardiac Catheter System in drug-resistant, symptomatic paroxysmal atrial fibrillation.
- Enrollment completed three months ahead of the original 9-month timeline; first patients were treated in April 2026, starting at St. Bernards Medical Center in Jonesboro, Arkansas.
- Primary safety and effectiveness endpoints will be assessed at 6 and 12 months post-ablation; Pulse expects to present pivotal data at a future medical society conference.
- Vivek Reddy, MD (Mount Sinai Fuster Heart Hospital) serves as national principal investigator; Devi Nair, MD led the first case; CMO David Kenigsberg credited investigator enthusiasm for the pace.

## SEC filing metadata
- accession: 0001437749-26-032271
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2026-10-07T13:06:30+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774926032271/0001437749-26-032271-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774926032271/plse20261002_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-032271
- JSON: https://secwatch.observer/filing/0001437749-26-032271.json
- Plain text: https://secwatch.observer/filing/0001437749-26-032271.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.